title: [Cost-effectiveness analysis of routine mumps immunization in Japan].
abstract: OBJECTIVE
  Mumps immunization is not included in routine immunization in Japan. We measured the cost-effectiveness of routine immunization.
  
  
  METHODS
  We surveyed outpatients prospectively from June 15, 2004, for 19 months in an area with a population of 100,000. Almost all of the 11 pediatric clinics and hospitals in this area cooperated. In 2006, we retrospectively surveyed all inpatients hospitalized for more than 24 hours and dying of mumps.
  
  
  RESULTS
  We collected data from 189 doctors who rated outpatients and 112 families. The disease burden for outpatients including family nursing was estimated to be 47.1 billion yen nationwide. We estimated the total number of inpatients as 4,596. The disease burden of inpatients including the cost of family nursing was estimated to be 1.35 billion yen. Adding cases of sequelae and death, the total disease burden was estimated to be 52.5 billion yen. The incremental benefit cost ratio for routine immunization is higher than 1 even in the lower bounds of the 95% confidence interval.
  
  
  CONCLUSIONS
  The incremental benefit cost ratio shows that the additional benefit due to routine immunization exceeds additional cost, emphasizing the benefits of routine mumps immunization.
authors.affiliation: National Institute of Infectious Diseases, Shimane Prefectual Central Hospital.
authors.forename: Tamie
authors.initials: T
authors.lastname: Sugawara
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Ohkusa
authors.forename: Keiko
authors.initials: K
authors.lastname: Taya
authors.forename: Kaoru
authors.initials: K
authors.lastname: Oikawa
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Haneda
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Kikuchi
authors.forename: Fumihide
authors.initials: F
authors.lastname: Kato
authors.forename: Seiji
authors.initials: S
authors.lastname: Yamaguchi
authors.forename: Tetuji
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Nakano
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Ihara
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Tutumi
authors.forename: Yoshizo
authors.initials: Y
authors.lastname: Asano
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kamiya
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Okabe
mesh_terms: D002648:Child; D003362:Cost-Benefit Analysis; D006801:Humans; D017589:Immunization Programs; D007564:Japan; D009108:Mumps Vaccine / Q000191:economics*; D011446:Prospective Studies; D012189:Retrospective Studies; D014611:Vaccination / Q000191:economics
chemical_list: D009108:Mumps Vaccine